Present data show, that the dual receptor agonist tirzepatide has exceeded the glucose-lowering and body weight-lowering effects compared to the established GLP-1 RAs (54, 66, 67, 71]
Beyond current indications, Alberta Blue Cross identifies potential future expanded uses including: Metabolic dysfunction-associated steatohepatitis (MASH) [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] Obstructive sleep apnea (OSA) [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] The insurer characterizes the developing GLP-1 pipeline as robust, with treatments described as more effective, broader in use, and longer between doses [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
Muscle preservation becomes harder with age, and not getting enough protein during rapid weight loss can accelerate sarcopenia
Cut down alcohol, smoking, and weed
*Personal results may vary based on our individualized health programs
Burns Fat, Not Muscle 9lbs avg